These biotech stocks will benefit as generative AI speeds up drug discovery, Jefferies says
Investors are underappreciating the effect generative artificial intelligence will have on biotech stocks, according to Jefferies. Biotech stocks have had a challenging couple of years, falling into a correction after an initial surge at the onset of the Covid-19 pandemic, as they navigated a higher interest rate environment. More recently, tariffs and staffing reductions at…
